Uncategorized

Summit slips on ivonescimab’s apparent interim miss in sign of investor frustration

Published

2 days ago

on

Summit Therapeutics’ stock price {$SMMT} tumbled nearly 20% after the closing bell Thursday afternoon, following an apparent statistical miss in part of a Phase 3 trial for its cancer drug ivonescimab.

In patients with a …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version